is desirable), while meeting quality requirements.
Avantor’ s J T Baker Direct Dispense packaging was recently developed to meet the customer need for automation and speed in plants. These disposable bags increase speed of production by allowing for assembly line type mixing, flexible bag sizes and no clumping of excipients, reducing manual intervention. The packaging is increasingly being adopted by customers around the globe who are sensitive to quality and time.
How has been the company ' s performance in India( including percentage of growth YOY) since last few years?
While Avantor, as a private company, does not disclose financial information, I can tell you that since 2011 Avantor India revenue has grown at a healthy pace, with CAGR significantly exceeding the industry trend of 6- 7 percent growth annually.
Please share with us your few unique experiences / learnings( customer behaviour, regulatory dealings or partners) in Indian market.
India has become a sourcing and manufacturing hub for generic drugs. Advanced countries, including the U. S., Europe and Japan, have very strict regulations( e. g., regulations established by the USFDA, MHRA UK, TGA Australia, WHO GMP, etc.). To meet regulatory muster, many pharma companies that sell into these advanced economies are seeking excipient suppliers that offer cGMP products that comply with Pharmacopeia specifications.
Avantor’ s capabilities and
“
Avantor’ s capabilities and experience in providing global regulatory documentation support at the product development stage has helped us become a preferred supplier.
experience in providing global regulatory documentation support at the product development stage has helped us become a preferred supplier.
How big is the market and how do you look at its potential opportunities?
Our J T Baker HPLE sugars are used in the manufacturing of biosimilars and vaccines. This market is at a nascent stage. The current base market is around 1.5- 2 MT and should grow at 18 percent per year.
What kind of future outlook do you have for your company, as well as the industry?
The pharmaceuticals industry in India is going through a major transformation, the key elements of which are:
• Small molecule drug manufacturers are targeting markets in the developed world to get a better return on their investments;
• Indian regulators are tightening quality standards in pharma sourcing and manufacturing;
• The FDA is increasing scrutiny of cGMP manufacturing for Indian generic / biosimilar exporters, including issuing warning letters, shutting down plants, etc.;
• Top Indian pharmaceutical companies are entering the CMO space and partnering with global pharma leaders; and
• Generic manufacturers are launching biosimilar offshoots to capture a higher-value customer segment( e. g., Oncology, Cardio etc.).
Due to these factors, pharma companies need excipients of the highest quality, which is exactly what we provide at Avantor. Some of our new products also help in reducing time and improving yield, giving our customers an edge to capture market share.
Avantor’ s advantage is the completeness of the support ecosystem we provide to customers: world-class cGMP manufacturing, high quality standards, technical support and product development through scientists and labs( including five labs in APAC), key account managers on the ground, and an effective supply chain through warehouses, planners and dealers. Due to these factors— and the high-growth markets in which we operate— we are extremely confident in our ability to generate industry-leading growth, while meeting the unique needs of our global customers.
BIOVOICENEWS. COM 31